Charles Gregory Vontz joins BioPharmX board of directors
Mr. Vontz most recently served as president and CEO of Topica Pharmaceuticals, which developed luliconazole for fungal infections of the skin, a product acquired by Medicis Pharmaceutical Corporation.
Earlier, Mr. Vontz was president and chief operating officer of Connetics Corporation, a public specialty pharmaceutical company, focusing on dermatology. Connetics was acquired by Stiefel Pharmaceuticals in late 2006.
Before joining Connetics, Mr. Vontz spent 12 years at Genentech in various senior marketing and product development roles.
He got his start in the pharmaceutical industry with Merck, Sharp and Dohme where he worked from 1985-1987 in sales and sales management.
Mr. Vontz is also a member of the board of directors for SinuSys Corporation.
He is a graduate of the University of Florida and received a Masters in Business Administration from the Haas School of Business at the University of California at Berkeley. ■
LATEST MOVES FROM California
- Verifone appoints Rowan Trollope to board of directors
- Catasys appoints Christopher Shirley as CFO
- Silicon Valley Bank promotes Michael Descheneaux to president
- Audentes Therapeutics appoints John T. Gray as SVP
- Natera appoints Gail Marcus to board
More inside POST
Swiss Re Q1 net income $656 million Earnings